サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1679137

経口固形剤受託製造市場：世界の産業分析、規模、シェア、成長、動向、予測、2025年～2032年

Oral Solid Dosage Contract Manufacturing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 173 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
経口固形剤受託製造市場：世界の産業分析、規模、シェア、成長、動向、予測、2025年～2032年
出版日: 2025年03月07日
発行: Persistence Market Research
ページ情報: 英文 173 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界の経口固形剤受託製造市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・促進要因・課題など、重要な市場ダイナミクスを徹底的に評価し、市場構造に関する詳細な洞察を提供しています。この調査レポートは、2025年から2032年までの世界の経口固形剤受託製造市場の予測成長軌道を概説する独占データと統計を掲載しています。

主な洞察

  • 経口固形剤受託製造市場規模（2025E）：380億米ドル
  • 予測市場規模（2032F）：579億米ドル
  • 世界市場成長率（CAGR 2025～2032年）：6.2%

経口固形剤受託製造市場 - 調査範囲：

錠剤、カプセル、ソフトジェルなどの経口固形製剤は、製薬業界で重要な役割を果たしています。経口固形剤受託製造市場は、これらの製剤の市場開拓と製造を専門とする製薬企業に製造委託サービスを提供しています。同市場は、ジェネリック医薬品メーカー、バイオテクノロジー企業、医薬品開発業務受託機関（CRO）のニーズに対応し、製剤開発、規制対応、大規模生産に関する専門知識を提供しています。市場成長の原動力は、経口固形製剤に対する需要の増加、慢性疾患の有病率の上昇、費用対効果の高い製造ソリューションへの注目の高まりです。

市場促進要因：

世界の経口固形剤受託製造市場は、製造コストの削減と業務効率の向上を目指す製薬企業の間でアウトソーシングの採用が増加していることなど、いくつかの主要な要因に後押しされています。製薬業界は高齢化社会の進展に伴う需要への対応に迫られており、製造のアウトソーシングにより、企業は研究開発などのコアコンピタンスに集中することができます。さらに、ジェネリック医薬品やバイオシミラーの需要は増加すると予想され、高品質で費用対効果の高い経口固形製剤の製造サービスへのニーズがさらに高まっています。さらに、連続製造や高度なコーティング技術などの製造技術の進歩により、製造プロセスの効率と品質が向上し、市場の成長が促進されています。

市場抑制要因：

有望な成長見通しとは裏腹に、経口固形剤受託製造市場は、規制遵守、知的財産保護、変動する原材料コストに関連する課題に直面しています。医薬品の製造と承認に関する厳しい規制要件は、新規参入企業にとって大きな参入障壁となり、運営コストを増大させます。さらに、独自の製剤や技術の保護など、知的財産に関する問題は継続的なリスクとなります。さらに、原材料価格の高騰やサプライチェーンの混乱は、特に資源が限られている発展途上地域において、医薬品製造受託企業の収益性に影響を与える可能性があります。

市場機会：

経口固形剤受託製造市場は、高品質で手頃な価格の医薬品に対する需要の高まりと、製薬業界におけるアウトソーシングへのシフトの進行により、大きな成長機会をもたらしています。慢性疾患の増加と高齢化に伴い、ジェネリック医薬品市場が拡大しており、信頼性の高い受託製造サービスへのニーズが高まっています。さらに、個別化医療の進展や新薬製剤の開発は、製造受託企業にとって革新的な市場ニーズに対応する機会を提供しています。戦略的パートナーシップ、最先端設備への投資、新興市場でのサービス拡大が、今後の成長の主な促進要因となると思われます。

本レポートで扱う主な質問

  • 世界の経口固形剤受託製造市場の成長を促す主な要因は何か？
  • アウトソーシング動向は市場の競合情勢にどのような影響を与えているか？
  • 経口固形製剤製造の形を変えつつある技術的進歩とは何か？
  • 経口固形剤受託製造市場に貢献している主要プレイヤーは誰で、市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界の経口固形剤受託製造市場の新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主な動向
  • マクロ経済要因
    • 世界のセクター別展望
    • 世界のGDP成長見通し
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値の洞察

  • 規制状況
  • 製品採用分析
  • バリューチェーン分析
  • 主要な取引と合併
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の経口固形剤受託製造市場の展望：

  • 主なハイライト
    • 市場規模（10億米ドル）と前年比成長率
    • 絶対的収益機会
  • 市場規模（10億米ドル）の分析と予測
    • 過去の市場規模（10億米ドル）分析、2019年～2024年
    • 現在の市場規模（10億米ドル）分析と予測、2025年～2032年
  • 世界の経口固形剤受託製造市場の展望：剤形
    • イントロダクション/主な調査結果
    • 過去の市場規模（10億米ドル）分析、剤形別、2019年～2024年
    • 現在の市場規模（10億米ドル）分析と予測、剤形別、2025～2032年
      • タブレット
        • 従来型
        • 放出制御型
        • チュアブルタブレット
        • 発泡錠
      • カプセル
        • ハードゼラチンカプセル
        • ソフトゼラチン
      • カプセル/ソフトジェル
      • 粉末・顆粒
      • ロゼンジ・トローチ
      • グミ
    • 市場の魅力分析：剤形
  • 世界の経口固形剤受託製造市場の展望：メカニズム
    • イントロダクション/主な調査結果
    • 過去の市場規模（10億米ドル）分析、メカニズム別、2019年～2024年
    • 現在の市場規模（10億米ドル）分析と予測、メカニズム別、2025～2032年
      • 即時放出
      • 遅延放出
      • 制御放出
    • 市場の魅力分析：メカニズム
  • 世界の経口固形剤受託製造市場の展望：アプリケーション
    • イントロダクション/主な調査結果
    • 過去の市場規模（10億米ドル）分析、アプリケーション別、2019～2024年
    • 現在の市場規模（10億米ドル）分析と予測、アプリケーション別、2025～2032年
      • 医薬品開発
      • 充填・仕上げ製品製造
      • 包装/ラベル
      • その他
    • 市場の魅力分析：アプリケーション
  • 世界の経口固形剤受託製造市場の展望：エンドユーザー
    • イントロダクション/主な調査結果
    • 過去の市場規模（10億米ドル）分析、エンドユーザー別、2019年～2024年
    • 現在の市場規模（10億米ドル）の分析と予測、エンドユーザー別、2025～2032年
      • 大手製薬会社/バイオテクノロジー企業
      • 中小規模の製薬・バイオテクノロジー企業
      • 新興/仮想製薬会社
      • 栄養補助食品会社
    • 市場の魅力分析：エンドユーザー

第5章 世界の経口固形剤受託製造市場の展望：地域

  • 主なハイライト
  • 過去の市場規模（10億米ドル）分析、地域別、2019年～2024年
  • 現在の市場規模（10億米ドル）分析と予測、地域別、2025～2032年
    • 北米
    • 欧州
    • 東アジア
    • 南アジアとオセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米の経口固形剤受託製造市場の見通し：

第7章 欧州の経口固形剤受託製造市場の見通し：

第8章 東アジアの経口固形剤受託製造市場の見通し：

第9章 南アジアおよびオセアニアの経口固形剤受託製造市場の見通し：

第10章 ラテンアメリカの経口固形剤受託製造市場の見通し：

第11章 中東およびアフリカの経口固形剤受託製造市場の見通し：

第12章 競合情勢

  • 市場シェア分析、2025年
  • 市場構造
    • 市場別の競合激化マップ
    • 競合ダッシュボード
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Recipharm
    • Aenova Holding
    • Catalent
    • AbbVie
    • Patheon NV（Thermo Fisher Scientific）
    • NextPharma
    • Lonza Group AG
    • Merck KGaA
    • Aurobindo Pharma Limited
    • Siegfried AG
    • Piramal Pharma Solutions
    • Corden Pharma
    • HERMES PHARMA GmbH
    • Medipaams India Private Limited
    • Alpex Pharma
    • Abaris Healthcare Pvt Ltd
    • Ardena Holdings NV
    • Aphena Pharma Solutions
    • Actiza Pharmaceutical Private Limited
    • Sunwin Healthcare PVT. LTD
    • Kosher Pharmaceuticals
    • Boehringer Ingelheim BioXcellence

第13章 付録

  • 調査手法
  • 調査の前提
  • 頭字語と略語
目次
Product Code: PMRREP25768

Persistence Market Research has recently released a comprehensive report on the worldwide market for oral solid dosage contract manufacturing. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global oral solid dosage contract manufacturing market from 2025 to 2032.

Key Insights:

  • Oral Solid Dosage Contract Manufacturing Market Size (2025E): US$ 38 Bn
  • Projected Market Value (2032F):US$ 57.9 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.2%

Oral Solid Dosage Contract Manufacturing Market - Report Scope:

Oral solid dosage forms, such as tablets, capsules, and soft gels, play a vital role in the pharmaceutical industry. The oral solid dosage contract manufacturing market offers outsourced production services to pharmaceutical companies that specialize in the development and production of these dosage forms. The market serves the needs of generic drug manufacturers, biotechnology companies, and contract research organizations (CROs), providing them with expertise in formulation development, regulatory compliance, and large-scale production. Market growth is driven by an increasing demand for oral solid dosage forms, the rising prevalence of chronic diseases, and the growing focus on cost-effective manufacturing solutions.

Market Growth Drivers:

The global oral solid dosage contract manufacturing market is propelled by several key factors, including the increasing adoption of outsourcing among pharmaceutical companies looking to reduce production costs and enhance operational efficiency. As the pharmaceutical industry faces growing pressure to meet the demands of a larger, aging population, the outsourcing of manufacturing allows companies to focus on their core competencies, such as research and development. Furthermore, the demand for generic drugs and biosimilars is expected to increase, further fueling the need for high-quality, cost-effective oral solid dosage manufacturing services. Additionally, advancements in manufacturing technologies, such as continuous manufacturing and advanced coating techniques, are improving the efficiency and quality of production processes, fostering market growth.

Market Restraints:

Despite the promising growth prospects, the oral solid dosage contract manufacturing market faces challenges related to regulatory compliance, intellectual property protection, and fluctuating raw material costs. Stringent regulatory requirements governing the manufacturing and approval of pharmaceutical products create significant barriers to entry for new market players and increase operational costs. Furthermore, issues related to intellectual property, such as the protection of proprietary formulations and technologies, present ongoing risks. In addition, rising raw material prices and supply chain disruptions can impact the profitability of contract manufacturers, particularly in developing regions where resources may be limited.

Market Opportunities:

The oral solid dosage contract manufacturing market presents significant growth opportunities driven by the increasing demand for high-quality, affordable medicines and the ongoing shift toward outsourcing in the pharmaceutical industry. With the rise in chronic diseases and the aging population, there is an expanding market for generic drugs, creating a need for reliable contract manufacturing services. Moreover, advancements in personalized medicine and the development of new drug formulations offer opportunities for contract manufacturers to innovate and cater to evolving market needs. Strategic partnerships, investments in state-of-the-art facilities, and the expansion of services in emerging markets will be key drivers of future growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the oral solid dosage contract manufacturing market globally?
  • How are outsourcing trends influencing the competitive landscape of the market?
  • What are the technological advancements that are reshaping oral solid dosage manufacturing?
  • Who are the key players contributing to the oral solid dosage contract manufacturing market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global oral solid dosage contract manufacturing market?

Competitive Intelligence and Business Strategy:

Leading players in the global oral solid dosage contract manufacturing market, including Lonza Group, Catalent, Inc., and Samsung Biologics, focus on expanding their manufacturing capabilities and service offerings to meet the diverse needs of pharmaceutical companies. These companies invest in the development of state-of-the-art manufacturing facilities, enhancing their ability to produce a wide range of oral solid dosage forms, including tablets, capsules, and controlled-release formulations. Moreover, they are actively engaged in strategic partnerships, acquisitions, and collaborations with pharmaceutical companies and research institutions to enhance their market position and drive innovation.

Key Companies Profiled:

  • Lonza Group
  • Catalent, Inc.
  • Samsung Biologics
  • Patheon
  • WuXi AppTec
  • Recipharm
  • Aenova Group
  • Boehringer Ingelheim
  • Siegfried Holding AG
  • Piramal Pharma Solutions

Oral Solid Dosage Contract Manufacturing Market Segmentation

By Dosage Form

  • Tablets
  • Capsules
  • Capsules/Softgels
  • Powders & Granules
  • Lozenges & Pastilles
  • Gummies

By Mechanism

  • Immediate Release
  • Delayed Release
  • Controlled Release

By Application

  • Drug Product Development
  • Fill & Finish Product Manufacturing
  • Packaging /Labelling

By End User

  • Big Pharma/Biotech Companies
  • Smalls & Medium-size Pharma/Biotech Companies
  • Emerging/virtual Pharma Companies
  • Nutraceutical Companies

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Oral Solid Dosage Contract Manufacturing Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Oral Solid Dosage Contract Manufacturing Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Oral Solid Dosage Contract Manufacturing Market Outlook: Dosage Form
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Dosage Form, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025-2032
      • 4.3.3.1. Tablets
        • 4.3.3.1.1. Conventional Release
        • 4.3.3.1.2. Modified Release
        • 4.3.3.1.3. Chewable Tablets
        • 4.3.3.1.4. Effervescent Tablets
      • 4.3.3.2. Capsules
        • 4.3.3.2.1. Hard Gelatin Capsules
        • 4.3.3.2.2. Soft Gelatin
      • 4.3.3.3. Capsules/Softgels
      • 4.3.3.4. Powders & Granules
      • 4.3.3.5. Lozenges & Pastilles
      • 4.3.3.6. Gummies
    • 4.3.4. Market Attractiveness Analysis: Dosage Form
  • 4.4. Global Oral Solid Dosage Contract Manufacturing Market Outlook: Mechanism
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Mechanism, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025-2032
      • 4.4.3.1. Immediate Release
      • 4.4.3.2. Delayed Release
      • 4.4.3.3. Controlled Release
    • 4.4.4. Market Attractiveness Analysis: Mechanism
  • 4.5. Global Oral Solid Dosage Contract Manufacturing Market Outlook: Application
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.5.3.1. Drug Product Development
      • 4.5.3.2. Fill & Finish Product Manufacturing
      • 4.5.3.3. Packaging /Labelling
      • 4.5.3.4. Others
    • 4.5.4. Market Attractiveness Analysis: Application
  • 4.6. Global Oral Solid Dosage Contract Manufacturing Market Outlook: End User
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.6.3.1. Big Pharma/Biotech Companies
      • 4.6.3.2. Smalls & Medium-size Pharma/Biotech Companies
      • 4.6.3.3. Emerging/virtual Pharma Companies
      • 4.6.3.4. Nutraceutical Companies
    • 4.6.4. Market Attractiveness Analysis: End User

5. Global Oral Solid Dosage Contract Manufacturing Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Oral Solid Dosage Contract Manufacturing Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Dosage Form
    • 6.2.3. By Mechanism
    • 6.2.4. By Application
    • 6.2.5. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025-2032
    • 6.4.1. Tablets
    • 6.4.2. Capsules
    • 6.4.3. Capsules/Softgels
    • 6.4.4. Powders & Granules
    • 6.4.5. Lozenges & Pastilles
    • 6.4.6. Gummies
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025-2032
    • 6.5.1. Immediate Release
    • 6.5.2. Delayed Release
    • 6.5.3. Controlled Release
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.6.1. Drug Product Development
    • 6.6.2. Fill & Finish Product Manufacturing
    • 6.6.3. Packaging /Labelling
    • 6.6.4. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.7.1. Big Pharma/Biotech Companies
    • 6.7.2. Smalls & Medium-size Pharma/Biotech Companies
    • 6.7.3. Emerging/virtual Pharma Companies
    • 6.7.4. Nutraceutical Companies
  • 6.8. Market Attractiveness Analysis

7. Europe Oral Solid Dosage Contract Manufacturing Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Dosage Form
    • 7.2.3. By Mechanism
    • 7.2.4. By Application
    • 7.2.5. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025-2032
    • 7.4.1. Tablets
    • 7.4.2. Capsules
    • 7.4.3. Capsules/Softgels
    • 7.4.4. Powders & Granules
    • 7.4.5. Lozenges & Pastilles
    • 7.4.6. Gummies
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025-2032
    • 7.5.1. Immediate Release
    • 7.5.2. Delayed Release
    • 7.5.3. Controlled Release
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.6.1. Drug Product Development
    • 7.6.2. Fill & Finish Product Manufacturing
    • 7.6.3. Packaging /Labelling
    • 7.6.4. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.7.1. Big Pharma/Biotech Companies
    • 7.7.2. Smalls & Medium-size Pharma/Biotech Companies
    • 7.7.3. Emerging/virtual Pharma Companies
    • 7.7.4. Nutraceutical Companies
  • 7.8. Market Attractiveness Analysis

8. East Asia Oral Solid Dosage Contract Manufacturing Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Dosage Form
    • 8.2.3. By Mechanism
    • 8.2.4. By Application
    • 8.2.5. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025-2032
    • 8.4.1. Tablets
    • 8.4.2. Capsules
    • 8.4.3. Capsules/Softgels
    • 8.4.4. Powders & Granules
    • 8.4.5. Lozenges & Pastilles
    • 8.4.6. Gummies
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025-2032
    • 8.5.1. Immediate Release
    • 8.5.2. Delayed Release
    • 8.5.3. Controlled Release
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.6.1. Drug Product Development
    • 8.6.2. Fill & Finish Product Manufacturing
    • 8.6.3. Packaging /Labelling
    • 8.6.4. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.7.1. Big Pharma/Biotech Companies
    • 8.7.2. Smalls & Medium-size Pharma/Biotech Companies
    • 8.7.3. Emerging/virtual Pharma Companies
    • 8.7.4. Nutraceutical Companies
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Oral Solid Dosage Contract Manufacturing Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Dosage Form
    • 9.2.3. By Mechanism
    • 9.2.4. By Application
    • 9.2.5. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025-2032
    • 9.4.1. Tablets
    • 9.4.2. Capsules
    • 9.4.3. Capsules/Softgels
    • 9.4.4. Powders & Granules
    • 9.4.5. Lozenges & Pastilles
    • 9.4.6. Gummies
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025-2032
    • 9.5.1. Immediate Release
    • 9.5.2. Delayed Release
    • 9.5.3. Controlled Release
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.6.1. Drug Product Development
    • 9.6.2. Fill & Finish Product Manufacturing
    • 9.6.3. Packaging /Labelling
    • 9.6.4. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.7.1. Big Pharma/Biotech Companies
    • 9.7.2. Smalls & Medium-size Pharma/Biotech Companies
    • 9.7.3. Emerging/virtual Pharma Companies
    • 9.7.4. Nutraceutical Companies
  • 9.8. Market Attractiveness Analysis

10. Latin America Oral Solid Dosage Contract Manufacturing Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Dosage Form
    • 10.2.3. By Mechanism
    • 10.2.4. By Application
    • 10.2.5. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025-2032
    • 10.4.1. Tablets
    • 10.4.2. Capsules
    • 10.4.3. Capsules/Softgels
    • 10.4.4. Powders & Granules
    • 10.4.5. Lozenges & Pastilles
    • 10.4.6. Gummies
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025-2032
    • 10.5.1. Immediate Release
    • 10.5.2. Delayed Release
    • 10.5.3. Controlled Release
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.6.1. Drug Product Development
    • 10.6.2. Fill & Finish Product Manufacturing
    • 10.6.3. Packaging /Labelling
    • 10.6.4. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.7.1. Big Pharma/Biotech Companies
    • 10.7.2. Smalls & Medium-size Pharma/Biotech Companies
    • 10.7.3. Emerging/virtual Pharma Companies
    • 10.7.4. Nutraceutical Companies
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Oral Solid Dosage Contract Manufacturing Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Dosage Form
    • 11.2.3. By Mechanism
    • 11.2.4. By Application
    • 11.2.5. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025-2032
    • 11.4.1. Tablets
    • 11.4.2. Capsules
    • 11.4.3. Capsules/Softgels
    • 11.4.4. Powders & Granules
    • 11.4.5. Lozenges & Pastilles
    • 11.4.6. Gummies
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025-2032
    • 11.5.1. Immediate Release
    • 11.5.2. Delayed Release
    • 11.5.3. Controlled Release
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.6.1. Drug Product Development
    • 11.6.2. Fill & Finish Product Manufacturing
    • 11.6.3. Packaging /Labelling
    • 11.6.4. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.7.1. Big Pharma/Biotech Companies
    • 11.7.2. Smalls & Medium-size Pharma/Biotech Companies
    • 11.7.3. Emerging/virtual Pharma Companies
    • 11.7.4. Nutraceutical Companies
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Recipharm
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Dosage Forms
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Aenova Holding
    • 12.3.3. Catalent
    • 12.3.4. AbbVie
    • 12.3.5. Patheon N.V. (Thermo Fisher Scientific)
    • 12.3.6. NextPharma
    • 12.3.7. Lonza Group AG
    • 12.3.8. Merck KGaA
    • 12.3.9. Aurobindo Pharma Limited
    • 12.3.10. Siegfried AG
    • 12.3.11. Piramal Pharma Solutions
    • 12.3.12. Corden Pharma
    • 12.3.13. HERMES PHARMA GmbH
    • 12.3.14. Medipaams India Private Limited
    • 12.3.15. Alpex Pharma
    • 12.3.16. Abaris Healthcare Pvt Ltd
    • 12.3.17. Ardena Holdings N.V
    • 12.3.18. Aphena Pharma Solutions
    • 12.3.19. Actiza Pharmaceutical Private Limited
    • 12.3.20. Sunwin Healthcare PVT. LTD
    • 12.3.21. Kosher Pharmaceuticals
    • 12.3.22. Boehringer Ingelheim BioXcellence

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations